NCT03566472 is a clinical trial of Continuous Glucose Monitoring System in Type2 Diabetes, sponsored by Nanjing First Hospital, Nanjing Medical University.

Who is sponsoring NCT03566472?

NCT03566472 is sponsored by Nanjing First Hospital, Nanjing Medical University.

What drugs are being tested in NCT03566472?

Interventions in NCT03566472: Continuous Glucose Monitoring System.

What condition does NCT03566472 study?

NCT03566472 studies Type2 Diabetes.

Is NCT03566472 still recruiting?

NCT03566472 is currently status unknown. Last updated 11 June 2019.

Last reviewed 2019-06-11 · How we verify

NCT03566472

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Blood Glucose Control in Patients With Type 2 Diabetes Treated With Glargine

Status unknown Last updated 11 June 2019

What this trial tests

trial testing Continuous Glucose Monitoring System in Type2 Diabetes in 100 participants. Status unknown.

Timeline

12 June 2018

Primary endpoint
30 December 2018

31 July 2019

Quick facts

Lead sponsor	Nanjing First Hospital, Nanjing Medical University
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	100
Start date	12 June 2018
Primary completion	30 December 2018
Estimated completion	31 July 2019
Sites	1 location across China

Drugs / interventions tested

Continuous Glucose Monitoring System

Conditions studied

Type2 Diabetes — all drugs for Type2 Diabetes →

Sponsor

Nanjing First Hospital, Nanjing Medical University

Who can join

Eligibility, any sex, with Type2 Diabetes. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Glargine is commonly used in insulin supplemental therapy in patients with type 2 diabetes(T2D) at present. This study aims to investigate the current status of blood glucose control in patients with T2D treated with glargine. Glycated hemoglobin(HbA1c) will be tested in these patients to assess the blood glucose control and Continuous Glucose Monitoring System (CGMS) will be used to investigate the glucose variability. Islet function, duration of diabetes, complications, exercise, insulin dose, oral medication regimen and insulin antibodies will be recorded in detail. This study will analysis the association between these clinical characteristics and blood glucose control.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Basal Insulin Reduces Glucose Variability and Hypoglycaemia Compared to Premixed Insulin in Type 2 Diabetes Patients: A Study Based on Continuous Glucose Monitoring Systems.
Wang H, Zhou Y, Wang Y, Cai T, et al · · 2022 · cited 7× · PMID 35574003 · DOI 10.3389/fendo.2022.791439

Verify or expand the search:

Other trials of Continuous Glucose Monitoring System

Trials testing the same drug.

NCT05131139 — Enhance Study: Evaluation of Accuracy and Safety of the Eversense CGM System With Enhanced Features · NA · unknown
NCT04812392 — Physical Inactivity Impacts on Blood Vessel Health and Glucose Levels in an Aging Population · NA · completed
NCT03955107 — The Effect of Continuous Glucose Monitoring on Glycemic Control and Pregnancy Outcomes in Gestational Diabetes Mellitus · Phase 4 · unknown
NCT03808376 — PROMISE Study: An Evaluation of an Implantable Continuous Glucose Sensor up to 180 Days · NA · completed
NCT03629704 — Relationship Between Blood Glucose Variability and Prognosis in Critically Ill Patients · unknown

Other recruiting trials for Type2 Diabetes

Currently open trials in the same condition.

NCT05277558 — Brain Health in Youth With Normal Weight, Overweight and Obesity at Risk for Type 2 Diabetes (T2D) · recruiting
NCT05015283 — Efficacy and Safety of One-anastomosis Versus Roux-en-Y Gastric Bypass for Type 2 Diabetes Remission · NA · recruiting
NCT05006508 — Prevention With the Health and Lifestyle Tool · NA · active not recruiting
NCT04717050 — Reducing Metabolic Dysregulation in Obese Latina Breast Cancer Survivors Using Physical Activity · NA · active not recruiting
NCT05220917 — Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study · active not recruiting

Other Nanjing First Hospital, Nanjing Medical University trials

Trials by the same sponsor.

NCT07349979 — PCI With Guideline-Directed Medical Therapy for HFpEF Patients With Ischemic Cardiomyopathy · NA · not yet recruiting
NCT07505056 — Jianpi Lishi Jiedu Granules for Prevention of Postoperative Recurrence in Colorectal Advanced Adenomas · Phase 3 · not yet recruiting
NCT07397234 — Thyroid Cartilage Plane VS Superior Laryngeal Nerve Space Block in Awake Tracheal Intubation · NA · not yet recruiting
NCT07455448 — Antibiotic Resistance of Helicobacter Pylori in Nanjing: A Cross-Sectional Study · completed
NCT07385885 — Ultrasound-guided Non-invasive Simulation in Anesthesia Residency Training · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03566472 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Nanjing First Hospital, Nanjing Medical University
Last refreshed: 11 June 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03566472.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing